AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-5. (Canceled).

6. (Currently amended) The TFA salt of a compound ~~according to Claim 1~~ which is selected from:

1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N,N-dimethyl-1-[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]metanamine;

1-{1-[4-(3-phenylbenzo[g]quinoxalin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N-{(3R)-1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]pyrrolidin-3-yl}-1,3-thiazole-5-carboxamide;

tert-butyl 1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]azetidin-3-ylcarbamate;

9-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-9H-purin-6-amine;

6-(4-{[4-(3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]methyl}phenyl)-7-phenyl-1H-imidazo[4,5-g]quinoxaline;



;



;



;



;



;



;



;



; and



or a stereoisomer thereof.

7. (Original) A compound which is selected from:

1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N,N-dimethyl-1-[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]metanamine;

1-{1-[4-(3-phenylbenzo[g]quinoxalin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N-{(3R)-1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]pyrrolidin-3-yl}-1,3-thiazole-5-carboxamide;

tert-butyl 1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]azetidin-3-ylcarbamate;

9-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-9H-purin-6-amine;

6-(4-{[4-(3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]methyl}phenyl)-7-phenyl-1H-imidazo[4,5-g]quinoxaline;



;



;



;



;


;


;


;


; and



or a pharmaceutically acceptable salt or a stereoisomer thereof.

8. (Canceled).

9. (Original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 7.

10-12. (Canceled).

13. (Currently amended) A method for treating ovarian, breast and prostate cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 7.

14-22. (Canceled).

23. (New) A compound of the Formula A:



wherein:

a is 0 or 1;
b is 0 or 1;
m is 0, 1 or 2;
n is 0, 1 or 2;
p is 0, 1, 2 or 3;
r is 0 or 1;
s is 0 or 1;



is selected from:



;

R^1 is independently selected from:

1) OH,
2) OC_1-C_6 alkyl, and
3) C_1-C_6 alkyl;

R^2 is independently selected from:

1) C_1-C_6 alkyl,
2) OH,
3) OC_1-C_6 alkyl,
4) CF_3,
5) CN, and
6) halogen;

said alkyl optionally substituted with one substituent selected from R^z;

R^3 and R^4 are: H;

R^5 and R^6 are independently selected from:

1) H,
2) $(C=O)O_bR^a$,
3) C_1-C_{10} alkyl,
4) aryl,
5) C_2-C_{10} alkenyl,

6) C_2-C_{10} alkynyl,
7) heterocyclyl,
8) C_3-C_8 cycloalkyl,
9) SO_2R^a, and
10) $(C=O)NR^b{}_2$,

said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^z, or

R^5 and R^6 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with Q and also optionally substituted with one or more substituents selected from R^z;

Q is selected from:



wherein R^z is selected from C_1-C_6 alkyl and halogen;

R^z is selected from:

1) $(C=O)_rO_s(C_1$-$C_{10})$alkyl,
2) $O_r(C_1$-$C_3)$perfluoroalkyl,
3) $(C_0$-$C_6)$alkylene-$S(O)_mR^a$,
4) oxo,
5) OH,
6) halo,
7) CN,
8) $(C=O)_rO_s(C_2$-$C_{10})$alkenyl,
9) $(C=O)_rO_s(C_2$-$C_{10})$alkynyl,
10) $(C=O)_rO_s(C_3$-$C_6)$cycloalkyl,

11) $(C=O)_rO_s(C_0\text{-}C_6)$alkylene-aryl,
12) $(C=O)_rO_s(C_0\text{-}C_6)$alkylene-heterocyclyl,
13) $(C=O)_rO_s(C_0\text{-}C_6)$alkylene-$N(R^b)_2$,
14) $C(O)R^a$,
15) $(C_0\text{-}C_6)$alkylene-CO_2R^a,
16) C(O)H,
17) $(C_0\text{-}C_6)$alkylene-CO_2H,
18) $C(O)N(R^b)_2$,
19) $S(O)_mR^a$,
20) $S(O)_2N(R^b)_2$,
21) $NR^c(C=O)O_bR^a$,
22) $O(C=O)O_bC_1\text{-}C_{10}$ alkyl,
23) $O(C=O)O_bC_3\text{-}C_8$ cycloalkyl,
24) $O(C=O)O_b$aryl, and
25) $O(C=O)O_b$-heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, $(C_1\text{-}C_6)$alkoxy, halogen, CO_2H, CN, $O(C=O)C_1\text{-}C_6$ alkyl, oxo, and $N(R^b)_2$;

R^a is substituted or unsubstituted $(C_1\text{-}C_6)$alkyl, substituted or unsubstituted $(C_2\text{-}C_6)$alkenyl, substituted or unsubstituted $(C_2\text{-}C_6)$alkynyl, substituted or unsubstituted $(C_3\text{-}C_6)$cycloalkyl, substituted or unsubstituted aryl, $(C_1\text{-}C_6)$perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

R^b is H, $(C_1\text{-}C_6)$alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, $(C_3\text{-}C_6)$cycloalkyl, $(C=O)OC_1\text{-}C_6$ alkyl, $(C=O)C_1\text{-}C_6$ alkyl or $S(O)_2R^a$;

R^c is selected from:

1) H,
2) $C_1\text{-}C_{10}$ alkyl,
3) aryl,
4) $C_2\text{-}C_{10}$ alkenyl,
5) $C_2\text{-}C_{10}$ alkynyl,

6) heterocyclyl,

7) C_3-C_8 cycloalkyl,

8) C_1-C_6 perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^z, or

or a pharmaceutically acceptable salt or a stereoisomer thereof.